Joint Symposium 23  
Oncology & Theranostics Committee / European Society of Digestive Oncology (ESDO)  
Friday, October 30, 10:40-12:10

Session Title  
New Diagnostic and Therapeutic Frontiers in Digestive Oncology

Chairperson  
Egesta Lopci (Milan, Italy)

Programme  
10:40 - 11:09  Eric van Cutsem (Leuven, Belgium / ESDO): Therapeutic Combinations in Digestive Oncology  
11:09 - 11:38  Côme Lepage (Dijon, France): Predictive Markers of Efficacy  
11:38 - 12:07  Lioe-Fee de Geus-Oei (Leiden, Netherlands): Combined Imaging Approaches - From Bench to Bedside

Educational Objectives  
1. Become familiar with the current standards and advanced therapeutic strategies in digestive oncology  
2. Obtain a basic understanding of the underlying mechanisms of efficacy and principal predictive markers of response  
3. Get a comprehensive insight of imaging applications with conventional and advanced approaches, including translational imaging

Summary  
Cancer treatment has experienced a radical transformation in the last decade moving from ‘one-size-fits-all’ cytotoxic therapies to tailored therapeutic approaches targeting specific molecular alterations in cancer cells. Digestive oncology has been similarly influenced by this evolution and multiple drugs, including immunotherapeutic and combined agents, have become along the way the standard of care. Precision medicine, based on the molecular tumour characteristics, is the main focus of current clinical research. Consequently, there is an increasing requirement for molecular biomarkers and predictive tests to ensure an optimal patient selection and treatment. Translational research, on counterpart, requires new prognostic and predictive markers for outcome and response through access to blood and tumor specimen of patients treated with the latest therapeutic approaches. In this context, a multidisciplinary management has become mandatory and the optimization of diagnostic modalities including response evaluation with modern imaging techniques and functional imaging with new PET tracers represents a real clinical demand.  
The purpose of the present joint symposium is to provide a comprehensive overview of the latest developments in cancer treatment in digestive oncology, by analyzing separately all established and potential biomarkers of response and by providing a thorough description of imaging approaches at present and future state.

Key Words  
Gastrointestinal tumors; digestive oncology; standard of care; advanced treatment; predictive factors; prognostic markers; response assessment; molecular imaging; metabolic response